Benfotiamine Encyclopedia — Scientific Background

What Is Benfotiamine?

Benfotiamine (CAS 22457-89-2), also known as S-benzoylthiamine O-monophosphate or benphothiamine, is a synthetic, fat-soluble, S-acyl derivative of thiamine (vitamin B1) with the molecular formula C₁₉H₂₃N₄O₆PS and a molecular weight of 466.45 g/mol. It is chemically characterized as an S-acyl thiamine obtained by acylative cleavage of the thiazole ring and O-phosphorylation, and is typically supplied as a white to off-white crystalline powder that is practically insoluble in water but soluble in many organic solvents.

The Fat-Soluble Thiamine Advantage

Benfotiamine represents a fundamentally different approach to thiamine supplementation compared to conventional water-soluble thiamine salts. Water-soluble thiamine salts (e.g., thiamine hydrochloride, thiamine nitrate) rely on saturable, rate-limited active transport mechanisms for intestinal absorption. As the dose increases, these transporters become saturated, and absorption efficiency declines. In contrast, benfotiamine is a lipophilic prodrug that is absorbed via passive diffusion, a non-saturable mechanism that allows for dose-proportional increases in absorption.

Benfotiamine has an open thiazole ring and a thioester bond that confer lipophilicity, enabling it to pass through intestinal membranes passively. Following oral administration, benfotiamine is dephosphorylated to S-benzoylthiamine by ecto-alkaline phosphatases in the small intestine. S-benzoylthiamine is lipophilic and passes easily through intestinal and endothelial cells and enters the bloodstream, where erythrocytes convert it to free thiamine. Part of S-benzoylthiamine is hydrolyzed in the liver to thiamine and benzoic acid by thioesterases. This mechanism allows benfotiamine to bypass the rate-limited active transport that constrains water-soluble thiamine absorption.

Mechanisms of Action

Thiamine Diphosphate (TDP) Elevation and Transketolase Activation

The primary mechanism of benfotiamine‘s therapeutic effects is its efficient conversion to thiamine diphosphate (TDP), the active cofactor form of vitamin B1. TDP is required for the activity of transketolase, a key enzyme in the pentose phosphate pathway that converts glucose metabolites into ribose-5-phosphate for nucleotide synthesis and NADPH for reductive biosynthesis. Oral administration of benfotiamine leads to higher TDP concentrations in erythrocytes, with a significant improvement of erythrocyte transketolase activity. Benfotiamine increases the levels of intracellular thiamine diphosphate, a cofactor necessary for the activation of transketolase, resulting in the reduction of tissue levels of AGEs.

Advanced Glycation End-Product (AGE) Inhibition

Benfotiamine reduces advanced glycation end-products (AGE) by 40% and completely prevents diabetes-induced glycoxidation products (CML) in preclinical studies. Unlike treatment with water-soluble thiamine nitrate, timely administration of the liposoluble prodrug benfotiamine significantly inhibited the development of functional damage and of AGE and CML formation in nerves of diabetic rats. The anti-AGE property of benfotiamine makes it effective for the treatment of diabetic neuropathy, nephropathy, and retinopathy.

Three Major Pathways of Hyperglycaemic Damage

Benfotiamine blocks three major biochemical pathways implicated in the pathogenesis of diabetic complications: the hexosamine pathway, AGE formation, and the DAG–PKC pathway. Treatment with benfotiamine plus alpha-lipoic acid completely normalised increased AGE formation, reduced increased monocyte hexosamine-modified proteins by 40%, and normalised the 70% decrease in prostacyclin synthase activity in patients with type 1 diabetes. These complementary mechanisms address multiple aspects of hyperglycaemia-induced cellular damage.

Neuroprotective Mechanisms

Preclinical studies have demonstrated that benfotiamine significantly inhibited the development of incipient diabetic nephropathy, neuropathy, and retinopathy in animal models. Benfotiamine was reported to prevent macro- and microvascular endothelial dysfunction and oxidative stress generation following a meal rich in AGEs in type 2 diabetic patients. The neuroprotective effects of benfotiamine have been corroborated by a number of studies, although the extent to which thiamine and other benfotiamine metabolites enter the brain remains inconclusive.

The Bioavailability Challenge

Despite its advantages over water-soluble thiamine, native benfotiamine presents formulation challenges. The compound has very low aqueous solubility (0.67 mg/mL in water, requiring sonication), which restricts its dispersibility in aqueous formulations and its practical application in liquid supplement formats. Free benfotiamine is practically insoluble in water but soluble in many organic solvents, requiring the use of DMSO or ethanol co-solvents for dissolution.

These limitations have driven the development of advanced delivery systems, including liposomal encapsulation. Liposomal delivery systems ensure 8 times greater absorption and bioavailability of active substances due to the added value of the liposomal carrier, compared to free and other conventional pharmaceutical carriers including tablets, suspensions, and capsules.

Liposomal Benfotiamine

Liposomal encapsulation of benfotiamine provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the benfotiamine molecule, forming a protective shell that enhances solubility, stability, and cellular uptake. This delivery system:

• Ensures 8 times greater absorption and bioavailability compared to conventional carriers

• Transforms poorly water-soluble benfotiamine into a water-dispersible powder

• Protects benfotiamine from premature degradation during digestive transit

• Provides sustained release for prolonged elevation of intracellular TDP levels

• Enhances cellular uptake through membrane fusion and lipid-mediated pathways

Liposomal formulations have been specifically developed to increase the absorption and bioavailability of active substances in comparison to free and other conventional pharmaceutical carriers such as tablets, suspensions, and capsules.

Clinical Evidence

Diabetic Neuropathy — Clinical Trials

The recommended daily dose of benfotiamine for the treatment of neuropathies is 300 mg, with doses as high as 900 mg/day delivered for 3 months and 300 mg/day administered for up to 2 years in clinical trials. In the BENDIP study, a benfotiamine dose of 300 mg two times a day (600 mg/day), but not 300 mg four times a day (1200 mg/day), was associated with an improvement of neuropathic symptoms after 5 weeks. A pilot study in early diabetic peripheral neuropathy used benfotiamine 100 mg four times a day for 3 weeks, and a 24-month trial of 300 mg/day benfotiamine has also been reported.

BOND Study — 12-Month Clinical Trial

The BOND study (BenfOthiamine in diabetic Neuropathy and Diabetes) was a randomized, double-blind, placebo-controlled, phase II trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological, and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. A fixed dose of benfotiamine 300 mg two times a day over 12 months was chosen to ensure adequate dosing throughout the entire trial period. The trial received favorable opinion by the Ethics Committee at the Faculty of Medicine of Heinrich Heine University, Düsseldorf, Germany, and was approved by the German Federal Institute for Drugs and Medical Devices.

Diabetic Nephropathy — Clinical Trial

A clinical study evaluated the effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. Compared to placebo, benfotiamine for 12 weeks did not result in significant reductions in plasma or urinary AGEs or plasma markers of endothelial dysfunction and low-grade inflammation in that specific study population.

Head-to-Head Pharmacokinetic Study

In a head-to-head pharmacokinetic study in healthy human volunteers, a single oral dose of benfotiamine resulted in a relative bioavailability of 1147.3% ± 490.3% for plasma thiamine compared to an equal dose of thiamine hydrochloride set as 100% baseline. Biokinetic data measured as area under the curve and maximal concentration in plasma and hemolysate after ingestion demonstrated a significantly improved bioavailability from the lipophilic derivative despite an ingested dose of only 40% as compared with the water-soluble salt.

Erythrocyte TDP and Transketolase Activity

Oral administration of benfotiamine leads to higher TDP concentrations in erythrocytes accompanied with a significant improvement of erythrocyte transketolase activity. In dialysis patients, the mean TDP concentration in erythrocytes increased from 158.7 ± 30.9 ng/mL initially to 325.8 ± 50.9 ng/mL. A study examining the pharmacokinetics of benfotiamine treatment in Alzheimer’s patients showed that maximum thiamine concentrations in the blood were reached 1–2 h after a single dose of benfotiamine, while ThMP and ThDP peaked at later time points (3.5–8 h for ThMP and 8–24 h for ThDP).

Safety and Regulatory

In clinical trials, no severe adverse events caused by benfotiamine were observed, except for one case of sudden cardiac death which was reported as a suspected unexpected serious adverse reaction possibly related to the investigational medicinal product. All other adverse events observed were usually only mild and did not require drug withdrawal. The expected rate of adverse events during benfotiamine treatment is 5%–10% of participants as a maximum, mainly gastrointestinal disorders or hypersensitivity reactions. There are no reports on teratogenic effects or adverse effects on development of the fetus, nor negative results on genotoxicity or carcinogenicity. Due to the extremely low toxicity of thiamine, different expert groups to date could not define adverse effect levels or tolerable upper intake level.

Regulatory status varies by region:

• United States — Benfotiamine is regulated as a dietary supplement ingredient and is not FDA-approved for any indication. It has been submitted as a new dietary ingredient (NDI) for premarket notification as a nutritional supplement source of thiamine (vitamin B1).

• European Union — Benfotiamine is considered a novel food under Article 3(2)(a)(ix) of Regulation (EU) 2015/2283, requiring pre-market authorisation before it can be placed on the EU market.

• Japan — Benfotiamine is classified as a third-class OTC drug and is approved as a pharmaceutical ingredient (JAN/INN).

• Global Standards — Benfotiamine is monographed in the Japanese Pharmacopoeia (JP) and is available with pharmaceutical-grade purity (98.0–102.0%). The BOND study was conducted under GCP guidelines with approval from the German Federal Institute for Drugs and Medical Devices.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

119$/KG

99$/KG